In the August 2005 Mayo Clinic Proceeding (8:1100-1101), there
is a letter to the editor by Guru Sonpavde that should convince
all of my readers about the potential benefit for using
Celebrex to treat prostate cancer. This case report describes
a 53-year-old man, who presented with urinary discomfort, low
back pain, and a bone scan showing widespread metastatic
disease. His PSA was 522, and Gleason score 9. He was started
on Lupron and Casodex, and after six months of therapy, PSA
dropped to 4. However, three months later, PSA rose to 22, and
then to 37. His Casodex was discontinued. Twelve months after
initiating treatment, his PSA was 55, and he was started on
ketoconazole/hydrocortisone. In spite of this, his PSA rose to
80 one month later, with the addition of worsening low back
pain. He refused to be treated with chemotherapy. Because of
his bone pain, he was started on Celebrex, 200 mg per day.
Within days, he had clinical improvement, with resolution of
his back pain. Two months after starting Celebrex, his PSA
dropped to 5.48. That represented his nadir PSA value. Four
months after starting Celebrex, his PSA was 11.5, and his dose
was increased to 200 mg twice each day. His PSA dropped to
10.4. Six months after starting Celebrex, his PSA was 22; it
was almost 80 when he started Celebrex.
This is certainly the most dramatic response to Celebrex as a
single agent that I have ever heard about or seen. Remember
that Celebrex is just one of the ingredients in my
antiangiogenic cocktail. I believe that when you treat
prostate cancer with only a single agent, it is fairly easy for
the cancer cells to mutate and become resistant. Using the
various ingredients in my antiangiogenic cocktail is a way to
help avoid the development of resistance.
=============================================(this is not the full text piece, partial)!
Not necessarily endorsing anything, just another example of alternative choices and possible effects, results that someone may be interested in knowing or doing.